Paw withdrawal thresholds (PWTs, mean ± 0.95 CIs) at the common dose of 200 ng of SN50 in chronic postischemia pain rats (A) and log dose–response curves (area under the curve [AUC] Δ-PWT × min ± 0.95 CIs) (B) for the groups of fed, fed/insulin (fed/ins), fed/insulin/dextrose (fed/ins/dex), and fed/dextrose (fed/dex) chronic postischemia pain rats. (C) Rotarod performance in control rats displayed for five daily training trials and for the post-SN50 administration on the sixth (filled bar). (A) The PWTs of the fed/ins group were significantly higher than the fed/ins/dex group at 30, 165, and, 210 min postinjection (*P < 0.05; **P < 0.01) and the fed group at 210 min postinjection (††P < 0.01). The PWTs of the fed group were significantly higher than in the fed/ins/dex group at 30 min postinjection (‡P < 0.05). The PWTs in the fed/dex group did not differ from baseline values at any time point. (B) Log dose–response curve for the area under the curve of the PWT after SN50 for the four groups of chronic postischemia pain rats. The slopes of the linear regressions were not statistically different (P > 0.05). The fed, fed/ins/dex, and fed/dex log dose–response curve exhibit a significant rightward shift compared with the fed/ins group. (C) Time (second ± 0.95 CIs) spent on the rotarod before and after treatment with SN50 600 ng. The drug did not affect rotarod performance (performance on day 6 is not statistically different than the performance on day 5; P > 0.05).